Trial Profile

A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Oct 2025 According to a Gilead Sciences Media Release, company to present data from phase 1b part of this study at the Liver Meeting 2025, hosted by the American Association for the Study of Liver Diseases (AASLD), November 7-11 in Washington, D.C.
30 Apr 2025 Status changed from active, no longer recruiting to completed.
29 Apr 2025 According to a Gilead Sciences Media Release,data from a phase 1a study will be presented at the European Association for the Study of the Liver (EASL) Congress, May 7-10, 2025, Amsterdam.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com